Akari Therapeutics News

Express News | Akari Therapeutics Said- On May 1 Began To Implement A Reduction-in-force Of Approximately 67% Of Its Total Workforce

Benzinga17:08 ET

Express News | Akari Therapeutics PLC - Expects Expenses Related to Reduction-in-Force to Be in Range of About $3.1 Mln to $3.2 Mln

Reuters17:07 ET

Express News | Akari Therapeutics PLC - Board Reduced Its Size to Five Members

Reuters17:07 ET

Express News | Akari Therapeutics PLC - Rachelle Jacques Resigned From Board of Directors

Reuters17:07 ET

Express News | Akari Therapeutics PLC - Reduction-in-Force Is Part of Operational Restructuring Plan and Includes Elimination of Certain Senior Management Positions

Reuters17:07 ET

Express News | Akari Therapeutics PLC - on May 1 Began to Implement a Reduction-in-Force of Approximately 67% of Its Total Workforce

Reuters17:06 ET

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga

MT NewswiresMay 6 11:19 ET

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower

European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde

MT NewswiresMay 3 11:11 ET

European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading

European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.25% to 1,364.91 on the S&P Europe Select ADR Index. From continental Europe,

MT NewswiresMay 2 11:29 ET

Akari Therapeutics Announces Post-Merger Strategic Advancements

TipRanksMay 1 17:23 ET

European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were trending modestly lower Wednesday morning, declining 0.36% to 1,359.56 on the S&P Europe Select ADR Index. From continental Euro

MT NewswiresMay 1 11:39 ET

Akari Gains Despite Leadership Change Amid Portfolio Shakeup

Seeking AlphaMay 1 10:08 ET

Express News | Akari Therapeutics Appoints Samir Patel As Interim CEO

BenzingaMay 1 08:05 ET

Express News | Akari Therapeutics PLC - Expects to Achieve Cost Savings Through Reduced Clinical Trial and Infrastructure Costs

ReutersMay 1 08:03 ET

Akari Therapeutics: Melissa Bradford-Klug Stepping Down as Chief Operating Officer >AKTX

Akari Therapeutics: Melissa Bradford-Klug Stepping Down as Chief Operating Officer >AKTX

Dow JonesMay 1 08:03 ET

Express News | Akari Therapeutics PLC - Rachelle Jacques Will Step Down as Akari's Chief Executive Officer

ReutersMay 1 08:02 ET

Express News | Samir R. Patel, M.d. Appointed Interim CEO for Akari Therapeutics

ReutersMay 1 08:01 ET

Press Release: Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity -- Prioritization of Peak's ADC cancer therapeutic platform technology and Akari'

Dow JonesMay 1 08:01 ET

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today anno

Akari TherapeuticsMay 1 00:00 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersPredictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved u

BenzingaApr 30 16:31 ET